{"protocolSection":{"identificationModule":{"nctId":"NCT01254422","orgStudyIdInfo":{"id":"CYD32"},"secondaryIdInfos":[{"id":"UTN: U1111-1115-6579","type":"OTHER","domain":"WHO"}],"organization":{"fullName":"Sanofi","class":"INDUSTRY"},"briefTitle":"Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia","officialTitle":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia"},"statusModule":{"statusVerifiedDate":"2022-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-12-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2012-09-28","type":"ACTUAL"},"completionDateStruct":{"date":"2013-01","type":"ACTUAL"},"studyFirstSubmitDate":"2010-12-03","studyFirstSubmitQcDate":"2010-12-03","studyFirstPostDateStruct":{"date":"2010-12-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-05-23","resultsFirstSubmitQcDate":"2019-05-23","resultsFirstPostDateStruct":{"date":"2019-07-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-03-15","lastUpdatePostDateStruct":{"date":"2022-03-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Sanofi","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.\n\nPrimary Objectives:\n\n* To describe the safety (in terms of solicited and unsolicited adverse events) of the CYD dengue vaccine in all participants after each injection.\n* To describe the antibody response to each dengue virus serotype post-injection 2 and post-injection 3.","detailedDescription":"Healthy participants aged 2 to 11 years received 3 vaccinations at pre-determined schedules and were followed-up for at least 6 months after the last vaccination."},"conditionsModule":{"conditions":["Dengue Fever","Dengue Hemorrhagic Fever"],"keywords":["Dengue fever","Dengue hemorrhagic fever","CYD dengue vaccine"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":250,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"CYD Dengue vaccine group","type":"EXPERIMENTAL","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.","interventionNames":["Biological: Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.","interventionNames":["Biological: Placebo: NaCl 0.9%"]}],"interventions":[{"type":"BIOLOGICAL","name":"Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus","description":"0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension","armGroupLabels":["CYD Dengue vaccine group"],"otherNames":["CYD Dengue vaccine"]},{"type":"BIOLOGICAL","name":"Placebo: NaCl 0.9%","description":"0.5 mL (at 0, 6, and 12 months), Subcutaneous suspension","armGroupLabels":["Placebo Group"],"otherNames":["Saline"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 Solicited injection site reactions: Pain: Incapacitating, unable to perform usual activities; Erythema and Swelling: \\>=50 millimeter (mm). Grade 3 Solicited systemic reactions: Fever: \\>=39°Degree Celsius (C); Headache, Malaise, Myalgia, and Asthenia: Significant: Prevents daily activity.","timeFrame":"Day 0 up to Day 14 post-any and each vaccination"},{"measure":"Percentage of Flavivirus-Immune Participants Reporting Solicited Injection Site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or Placebo Vaccine","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Flavivirus-Immune participants were defined as participants with quantified antibodies against Japanese encephalitis and/or against at least 1 serotype with parental dengue virus strains (serotype 1, 2, 3, and 4) in the baseline sample.","timeFrame":"Day 0 up to Day 14 post-each vaccination"},{"measure":"Percentage of Flavivirus-Naïve Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or a Placebo Vaccine","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Flavivirus-Naive participants were defined as participants without quantified antibodies against Japanese encephalitis and without antibody quantified against all serotypes (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","timeFrame":"Day 0 up to Day 14 post-each vaccination"},{"measure":"Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each dengue serotype (1,2, 3 and 4) and was assessed using the Dengue Plaque Reduction Neutralization Test (PRNT).","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3"},{"measure":"Percentage of Participants With Seropositivity Against at Least One, Two, Three, or the Four Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each dengue serotype (1, 2, 3, and 4) and was assessed using the dengue PRNT.","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3"},{"measure":"Geometric Mean Titers (GMTs) Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"GMTs of antibodies against the dengue virus serotypes (1, 2, 3, and 4) were assessed using the dengue PRNT.","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3"},{"measure":"Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Immune Participants","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each serotype (1, 2, 3, and 4) and was assessed using the Dengue PRNT. Flavivirus-Immune participants were defined as participants with quantified antibodies against Japanese encephalitis and/or against at least 1 serotype (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3"},{"measure":"Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Naive Participants","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each serotype (1, 2, 3, and 4) and was assessed using the Dengue PRNT. Flavivirus naïve participants were defined as participants without quantified antibodies against Japanese encephalitis and without quantified antibodies against all serotypes (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3"},{"measure":"GMTs of Flavivirus-Immune Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"GMTs of antibodies against the dengue virus serotypes (1, 2, 3, and 4) were assessed using the Dengue PRNT. Flavivirus-Immune participants were defined as participants with quantified antibodies against Japanese encephalitis and/or against at least 1 serotype (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3"},{"measure":"GMT of Flavivirus-Naïve Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"GMTs of antibodies against the dengue virus serotypes (1, 2, 3, and 4) were assessed using the Dengue PRNT. Flavivirus-Naive participants were defined as participants without quantified antibodies against Japanese encephalitis and without antibody quantified against all serotypes (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","timeFrame":"Pre-Injection 1 and Post- Injections 2 and 3"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged 2 to 11 years on the day of inclusion\n* Assent form was signed and dated by the participant (for participants ≥ 7 years) and informed consent form was signed and dated by the parent(s) or another legally accepted representative, and by an independent witness if the two parents or legally accepted representative were illiterate\n* Participant and parent/legally accepted representative were able to attend all scheduled visits to comply with all trial procedures\n* Participants in good health, based on medical history and physical examination\n* For a female participant of childbearing potential, use of an effective method of contraception or abstinence for at least 4 weeks prior to the first vaccination, until at least 4 weeks after the last vaccination\n\nExclusion Criteria:\n\n* Known pregnancy, or a positive urine pregnancy test (for female participant of child-bearing potential only)\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Planned receipt of any vaccine in the 4 weeks following the trial first vaccination, except for pandemic influenza vaccination\n* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Seropositivity for human immunodeficiency virus (HIV) reported by the parent/legally acceptable representative\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances\n* Chronic illness that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion\n* Participants who plan to move to another country/region within the 18 coming months\n* Identified as a child (adopted or natural) of the Investigator or of site employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Sanofi Pasteur Singapore","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Ipoh, Perak","zip":"30990","country":"Malaysia"},{"city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"city":"Kuching, Sarawak","zip":"93586","country":"Malaysia","geoPoint":{"lat":1.55,"lon":110.33333}},{"city":"Negeri Sembilan","zip":"70300","country":"Malaysia"}]},"referencesModule":{"references":[{"pmid":"24135573","type":"RESULT","citation":"Hss AS, Koh MT, Tan KK, Chan LG, Zhou L, Bouckenooghe A, Crevat D, Hutagalung Y. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study. Vaccine. 2013 Dec 2;31(49):5814-21. doi: 10.1016/j.vaccine.2013.10.013. Epub 2013 Oct 14."}],"seeAlsoLinks":[{"label":"Related Info","url":"http://www.sanofipasteur.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 250 participants who met all of the inclusion criteria and none of the exclusion criteria were enrolled and randomized.","recruitmentDetails":"Study participants were enrolled from 02 December 2010 to 10 February 2011 at 4 clinical sites in Malaysia.","groups":[{"id":"FG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections (Inj.) of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"FG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"199"},{"groupId":"FG001","numSubjects":"51"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"196"},{"groupId":"FG001","numSubjects":"50"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Serious adverse event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis was performed on all randomized participants who were randomly assigned to CYD Dengue vaccine Group or Placebo Group.","groups":[{"id":"BG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"BG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"199"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"250"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Years","classes":[{"title":"2 to 5 years","categories":[{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"125"}]}]},{"title":"6 to 11 years","categories":[{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"125"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"122"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"128"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Reporting Solicited Injection-site and Systemic Reactions Following Any and Each Vaccination With Either CYD Dengue Vaccine or a Placebo","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Grade 3 Solicited injection site reactions: Pain: Incapacitating, unable to perform usual activities; Erythema and Swelling: \\>=50 millimeter (mm). Grade 3 Solicited systemic reactions: Fever: \\>=39°Degree Celsius (C); Headache, Malaise, Myalgia, and Asthenia: Significant: Prevents daily activity.","populationDescription":"Analysis was performed on safety analysis set which included participants who received any dose of CYD dengue vaccine or placebo and were analyzed according to the treatment received at this injection. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Day 0 up to Day 14 post-any and each vaccination","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"classes":[{"title":"Inj. site Pain; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"69.3"},{"groupId":"OG001","value":"56.9"}]}]},{"title":"Grade 3 Inj. site Pain; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Erythema; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.7"},{"groupId":"OG001","value":"49.0"}]}]},{"title":"Grade 3 Inj. site Erythema; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Swelling; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.7"},{"groupId":"OG001","value":"35.3"}]}]},{"title":"Grade 3 Inj. site Swelling; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Pain; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"41.4"},{"groupId":"OG001","value":"27.5"}]}]},{"title":"Grade 3 Inj. site Pain; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Erythema; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.2"},{"groupId":"OG001","value":"23.5"}]}]},{"title":"Grade 3 Inj. site Erythema; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Swelling; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.7"},{"groupId":"OG001","value":"21.6"}]}]},{"title":"Grade 3 Inj. site Swelling; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Pain; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.2"},{"groupId":"OG001","value":"26.0"}]}]},{"title":"Grade 3 Inj. site Pain; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Erythema; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.0"},{"groupId":"OG001","value":"32.0"}]}]},{"title":"Grade 3 Inj. site Erythema; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Swelling; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.2"},{"groupId":"OG001","value":"10.0"}]}]},{"title":"Grade 3 Inj. site Swelling; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Pain; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40.0"},{"groupId":"OG001","value":"38.0"}]}]},{"title":"Grade 3 Inj. site Pain; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Erythema; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.6"},{"groupId":"OG001","value":"24.0"}]}]},{"title":"Grade 3 Inj. site Erythema; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Inj. site Swelling; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.0"},{"groupId":"OG001","value":"24.0"}]}]},{"title":"Grade 3 Inj. site Swelling; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Asthenia; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.2"},{"groupId":"OG001","value":"33.3"}]}]},{"title":"Grade 3 Asthenia; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.3"},{"groupId":"OG001","value":"19.6"}]}]},{"title":"Grade 3 Fever; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.6"},{"groupId":"OG001","value":"3.9"}]}]},{"title":"Headache; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"52.3"},{"groupId":"OG001","value":"39.2"}]}]},{"title":"Grade 3 Headache; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"2.0"}]}]},{"title":"Malaise; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.3"},{"groupId":"OG001","value":"41.2"}]}]},{"title":"Grade 3 Malaise; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.7"},{"groupId":"OG001","value":"31.4"}]}]},{"title":"Grade 3 Myalgia; Post-Any Inj.","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Asthenia; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.1"},{"groupId":"OG001","value":"19.6"}]}]},{"title":"Grade 3 Asthenia; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.6"},{"groupId":"OG001","value":"8.2"}]}]},{"title":"Grade 3 Fever; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"4.1"}]}]},{"title":"Headache; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.2"},{"groupId":"OG001","value":"27.5"}]}]},{"title":"Grade 3 Headache; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Malaise; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.4"},{"groupId":"OG001","value":"29.4"}]}]},{"title":"Grade 3 Malaise; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7"},{"groupId":"OG001","value":"23.5"}]}]},{"title":"Grade 3 Myalgia; Post-Inj. 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"198"},{"groupId":"OG001","value":"51"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Asthenia; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.9"},{"groupId":"OG001","value":"6.0"}]}]},{"title":"Grade 3 Asthenia; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.2"},{"groupId":"OG001","value":"10.2"}]}]},{"title":"Grade 3 Fever; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.0"},{"groupId":"OG001","value":"16.0"}]}]},{"title":"Grade 3 Headache; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"2.0"}]}]},{"title":"Malaise; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.9"},{"groupId":"OG001","value":"6.0"}]}]},{"title":"Grade 3 Malaise; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.8"},{"groupId":"OG001","value":"8.0"}]}]},{"title":"Grade 3 Myalgia; Post-Inj. 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"197"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Asthenia; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.0"},{"groupId":"OG001","value":"12.0"}]}]},{"title":"Grade 3 Asthenia; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.5"},{"groupId":"OG001","value":"2.0"}]}]},{"title":"Grade 3 Fever; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.7"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.6"},{"groupId":"OG001","value":"14.0"}]}]},{"title":"Grade 3 Headache; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Malaise; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.5"},{"groupId":"OG001","value":"12.0"}]}]},{"title":"Grade 3 Malaise; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Myalgia; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.4"},{"groupId":"OG001","value":"10.0"}]}]},{"title":"Grade 3 Myalgia; Post-Inj. 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0"},{"groupId":"OG001","value":"0.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Flavivirus-Immune Participants Reporting Solicited Injection Site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or Placebo Vaccine","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Flavivirus-Immune participants were defined as participants with quantified antibodies against Japanese encephalitis and/or against at least 1 serotype with parental dengue virus strains (serotype 1, 2, 3, and 4) in the baseline sample.","populationDescription":"Analysis was performed on safety analysis set. Here, \"overall number of participants analyzed\" signifies participants evaluable for this outcome measure and 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Day 0 up to Day 14 post-each vaccination","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"31"}]}],"classes":[{"title":"Injection site Pain; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.5"},{"groupId":"OG001","value":"29.0"}]}]},{"title":"Injection site Erythema; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.5"},{"groupId":"OG001","value":"29.0"}]}]},{"title":"Injection site Swelling; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.6"},{"groupId":"OG001","value":"22.6"}]}]},{"title":"Asthenia; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.9"},{"groupId":"OG001","value":"25.8"}]}]},{"title":"Fever; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.7"},{"groupId":"OG001","value":"13.3"}]}]},{"title":"Malaise; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.2"},{"groupId":"OG001","value":"38.7"}]}]},{"title":"Myalgia; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7"},{"groupId":"OG001","value":"25.8"}]}]},{"title":"Headache; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"111"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.9"},{"groupId":"OG001","value":"29.0"}]}]},{"title":"Injection site Pain; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.2"},{"groupId":"OG001","value":"32.3"}]}]},{"title":"Injection site Erythema; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.5"},{"groupId":"OG001","value":"29.0"}]}]},{"title":"Injection site Swelling; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.1"},{"groupId":"OG001","value":"16.1"}]}]},{"title":"Asthenia; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.8"},{"groupId":"OG001","value":"9.7"}]}]},{"title":"Fever; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.2"},{"groupId":"OG001","value":"9.7"}]}]},{"title":"Malaise; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.1"},{"groupId":"OG001","value":"3.2"}]}]},{"title":"Myalgia; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.1"},{"groupId":"OG001","value":"12.9"}]}]},{"title":"Headache; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"110"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.8"},{"groupId":"OG001","value":"12.9"}]}]},{"title":"Injection site Pain; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.3"},{"groupId":"OG001","value":"41.9"}]}]},{"title":"Injection site Erythema; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"21.3"},{"groupId":"OG001","value":"22.6"}]}]},{"title":"Injection site Swelling; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.7"},{"groupId":"OG001","value":"22.6"}]}]},{"title":"Asthenia; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13.9"},{"groupId":"OG001","value":"16.1"}]}]},{"title":"Fever; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Malaise; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.5"},{"groupId":"OG001","value":"16.1"}]}]},{"title":"Myalgia; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.8"},{"groupId":"OG001","value":"16.1"}]}]},{"title":"Headache; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"19.4"},{"groupId":"OG001","value":"19.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Flavivirus-Naïve Participants Reporting Solicited Injection-site and Systemic Reactions Following Each Vaccination With CYD Dengue Vaccine or a Placebo Vaccine","description":"Solicited injection site reactions: Pain, Erythema, and Swelling. Solicited systemic reactions: Fever, Headache, Malaise, Myalgia, and Asthenia. Flavivirus-Naive participants were defined as participants without quantified antibodies against Japanese encephalitis and without antibody quantified against all serotypes (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","populationDescription":"Analysis was performed on safety analysis set. Here, ''overall number of participants analyzed\" signifies participants evaluable for this outcome measure and 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Day 0 up to Day 14 post-each vaccination","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"classes":[{"title":"Injection site Pain; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.5"},{"groupId":"OG001","value":"25.0"}]}]},{"title":"Injection site Erythema; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.8"},{"groupId":"OG001","value":"15.0"}]}]},{"title":"Injection site Swelling; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.0"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Asthenia; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"28.4"},{"groupId":"OG001","value":"10.0"}]}]},{"title":"Fever; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.5"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Malaise; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"34.1"},{"groupId":"OG001","value":"15.0"}]}]},{"title":"Myalgia; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.7"},{"groupId":"OG001","value":"20.0"}]}]},{"title":"Headache; Post-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"20"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.5"},{"groupId":"OG001","value":"25.0"}]}]},{"title":"Injection site Pain; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"48.3"},{"groupId":"OG001","value":"15.8"}]}]},{"title":"Injection site Erythema; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"42.5"},{"groupId":"OG001","value":"36.8"}]}]},{"title":"Injection site Swelling; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Asthenia; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.4"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Fever; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.5"},{"groupId":"OG001","value":"11.1"}]}]},{"title":"Malaise; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.4"},{"groupId":"OG001","value":"10.5"}]}]},{"title":"Myalgia; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.4"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"29.9"},{"groupId":"OG001","value":"21.1"}]}]},{"title":"Injection site Pain; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47.1"},{"groupId":"OG001","value":"31.6"}]}]},{"title":"Injection site Erythema; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.4"},{"groupId":"OG001","value":"26.3"}]}]},{"title":"Injection site Swelling; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.3"},{"groupId":"OG001","value":"26.3"}]}]},{"title":"Asthenia; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25.3"},{"groupId":"OG001","value":"5.3"}]}]},{"title":"Fever; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.2"},{"groupId":"OG001","value":"5.3"}]}]},{"title":"Malaise; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"5.3"}]}]},{"title":"Myalgia; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"20.7"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Headache; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.4"},{"groupId":"OG001","value":"5.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each dengue serotype (1,2, 3 and 4) and was assessed using the Dengue Plaque Reduction Neutralization Test (PRNT).","populationDescription":"Analysis was performed on Full analysis set which included participants who received at least one injection of CYD dengue vaccine or placebo and had at least one valid post-injection serology result. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"classes":[{"title":"Serotype 1; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"31.1"},{"groupId":"OG001","value":"32.0"}]}]},{"title":"Serotype 1; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"90.3"},{"groupId":"OG001","value":"34.0"}]}]},{"title":"Serotype 1; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.4"},{"groupId":"OG001","value":"30.0"}]}]},{"title":"Serotype 2; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27.6"},{"groupId":"OG001","value":"30.0"}]}]},{"title":"Serotype 2; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"94.9"},{"groupId":"OG001","value":"34.0"}]}]},{"title":"Serotype 2; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.9"},{"groupId":"OG001","value":"34.0"}]}]},{"title":"Serotype 3; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"36.7"},{"groupId":"OG001","value":"36.7"}]}]},{"title":"Serotype 3; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.5"},{"groupId":"OG001","value":"32.0"}]}]},{"title":"Serotype 3; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.0"},{"groupId":"OG001","value":"34.0"}]}]},{"title":"Serotype 4; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.0"},{"groupId":"OG001","value":"30.0"}]}]},{"title":"Serotype 4; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.8"},{"groupId":"OG001","value":"32.0"}]}]},{"title":"Serotype 4; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"98.0"},{"groupId":"OG001","value":"28.0"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Seropositivity Against at Least One, Two, Three, or the Four Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each dengue serotype (1, 2, 3, and 4) and was assessed using the dengue PRNT.","populationDescription":"Analysis was performed on Full analysis set.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"classes":[{"title":"At least 1 serotype; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"44.9"},{"groupId":"OG001","value":"48.0"}]}]},{"title":"At least 1 serotype; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"46.0"}]}]},{"title":"At least 1 serotype; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"42.0"}]}]},{"title":"At least 2 serotypes; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"29.1"},{"groupId":"OG001","value":"28.0"}]}]},{"title":"At least 2 serotypes; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"99.0"},{"groupId":"OG001","value":"34.0"}]}]},{"title":"At least 2 serotypes; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"32.0"}]}]},{"title":"At least 3 serotypes; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"25.5"},{"groupId":"OG001","value":"28.0"}]}]},{"title":"At least 3 serotypes; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"96.4"},{"groupId":"OG001","value":"28.0"}]}]},{"title":"At least 3 serotypes; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"98.5"},{"groupId":"OG001","value":"30.0"}]}]},{"title":"All 4 serotypes; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"19.9"},{"groupId":"OG001","value":"24.0"}]}]},{"title":"All 4 serotypes; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"80.1"},{"groupId":"OG001","value":"24.0"}]}]},{"title":"All 4 serotypes; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"91.8"},{"groupId":"OG001","value":"22.0"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"GMTs of antibodies against the dengue virus serotypes (1, 2, 3, and 4) were assessed using the dengue PRNT.","populationDescription":"Analysis was performed on Full analysis set. Here, 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers (1/dilution)","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"classes":[{"title":"Serotype 1; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","lowerLimit":"11.5","upperLimit":"20.4"},{"groupId":"OG001","value":"18.6","lowerLimit":"9.69","upperLimit":"35.8"}]}]},{"title":"Serotype 1; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"119","lowerLimit":"90.7","upperLimit":"155"},{"groupId":"OG001","value":"21.0","lowerLimit":"10.6","upperLimit":"41.9"}]}]},{"title":"Serotype 1; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"151","lowerLimit":"121","upperLimit":"188"},{"groupId":"OG001","value":"18.9","lowerLimit":"9.94","upperLimit":"35.8"}]}]},{"title":"Serotype 2; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.9","lowerLimit":"11.8","upperLimit":"21.3"},{"groupId":"OG001","value":"18.6","lowerLimit":"10.0","upperLimit":"34.5"}]}]},{"title":"Serotype 2; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"160","lowerLimit":"127","upperLimit":"203"},{"groupId":"OG001","value":"17.9","lowerLimit":"9.91","upperLimit":"32.2"}]}]},{"title":"Serotype 2; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"180","lowerLimit":"146","upperLimit":"221"},{"groupId":"OG001","value":"16.3","lowerLimit":"9.59","upperLimit":"27.7"}]}]},{"title":"Serotype 3; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"49"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","lowerLimit":"12.3","upperLimit":"19.9"},{"groupId":"OG001","value":"15.9","lowerLimit":"9.57","upperLimit":"26.5"}]}]},{"title":"Serotype 3; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"196","lowerLimit":"163","upperLimit":"235"},{"groupId":"OG001","value":"15.9","lowerLimit":"9.27","upperLimit":"27.4"}]}]},{"title":"Serotype 3; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"193","lowerLimit":"161","upperLimit":"231"},{"groupId":"OG001","value":"16.3","lowerLimit":"9.81","upperLimit":"27.0"}]}]},{"title":"Serotype 4; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.92","lowerLimit":"8.17","upperLimit":"12.0"},{"groupId":"OG001","value":"12.3","lowerLimit":"7.96","upperLimit":"19.0"}]}]},{"title":"Serotype 4; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"110","lowerLimit":"88.9","upperLimit":"136"},{"groupId":"OG001","value":"13.3","lowerLimit":"7.94","upperLimit":"22.1"}]}]},{"title":"Serotype 4; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"196"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"114","lowerLimit":"97.0","upperLimit":"134"},{"groupId":"OG001","value":"10.9","lowerLimit":"7.34","upperLimit":"16.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Immune Participants","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each serotype (1, 2, 3, and 4) and was assessed using the Dengue PRNT. Flavivirus-Immune participants were defined as participants with quantified antibodies against Japanese encephalitis and/or against at least 1 serotype (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","populationDescription":"Analysis was performed on Full analysis set. Here, \"overall number of participants analyzed\" signifies participants evaluable for this outcome measure and 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"classes":[{"title":"Serotype 1; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.0"},{"groupId":"OG001","value":"51.6"}]}]},{"title":"Serotype 1; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.3"},{"groupId":"OG001","value":"48.4"}]}]},{"title":"Serotype 1; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.2"},{"groupId":"OG001","value":"41.9"}]}]},{"title":"Serotype 2; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49.5"},{"groupId":"OG001","value":"48.4"}]}]},{"title":"Serotype 2; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"96.3"},{"groupId":"OG001","value":"54.8"}]}]},{"title":"Serotype 2; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.2"},{"groupId":"OG001","value":"48.4"}]}]},{"title":"Serotype 3; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.1"},{"groupId":"OG001","value":"60.0"}]}]},{"title":"Serotype 3; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"51.6"}]}]},{"title":"Serotype 3; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"99.1"},{"groupId":"OG001","value":"48.4"}]}]},{"title":"Serotype 4; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"43.1"},{"groupId":"OG001","value":"48.4"}]}]},{"title":"Serotype 4; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"97.2"},{"groupId":"OG001","value":"45.2"}]}]},{"title":"Serotype 4; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"41.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Seropositivity Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo: Flavivirus-Naive Participants","description":"Seropositivity was defined as participants achieving neutralizing antibody titers \\>=10 (1/dilution) against each serotype (1, 2, 3, and 4) and was assessed using the Dengue PRNT. Flavivirus naïve participants were defined as participants without quantified antibodies against Japanese encephalitis and without quantified antibodies against all serotypes (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","populationDescription":"Analysis was performed on Full analysis set. Here, \"overall number of participants analyzed\" signifies participants evaluable for this outcome measure and 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"classes":[{"title":"Serotype 1; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 1; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"82.8"},{"groupId":"OG001","value":"10.5"}]}]},{"title":"Serotype 1; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"95.4"},{"groupId":"OG001","value":"10.5"}]}]},{"title":"Serotype 2; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 2; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"93.1"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 2; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"96.6"},{"groupId":"OG001","value":"10.5"}]}]},{"title":"Serotype 3; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 3; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"96.6"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 3; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"98.9"},{"groupId":"OG001","value":"10.5"}]}]},{"title":"Serotype 4; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}]},{"title":"Serotype 4; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"85.1"},{"groupId":"OG001","value":"10.5"}]}]},{"title":"Serotype 4; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"95.4"},{"groupId":"OG001","value":"5.3"}]}]}]},{"type":"PRIMARY","title":"GMTs of Flavivirus-Immune Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"GMTs of antibodies against the dengue virus serotypes (1, 2, 3, and 4) were assessed using the Dengue PRNT. Flavivirus-Immune participants were defined as participants with quantified antibodies against Japanese encephalitis and/or against at least 1 serotype (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","populationDescription":"Analysis was performed on Full analysis set. Here, \"overall number of participants analyzed\" signifies participants evaluable for this outcome measure and 'number analyzed' = participants with available data for each specified category.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers (1/dilution)","timeFrame":"Pre-Injection 1 and Post-Injections 2 and 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"classes":[{"title":"Serotype 1; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"37.5","lowerLimit":"24.0","upperLimit":"58.6"},{"groupId":"OG001","value":"41.7","lowerLimit":"16.0","upperLimit":"109"}]}]},{"title":"Serotype 1; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"248","lowerLimit":"171","upperLimit":"361"},{"groupId":"OG001","value":"45.4","lowerLimit":"16.3","upperLimit":"127"}]}]},{"title":"Serotype 1; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"247","lowerLimit":"178","upperLimit":"343"},{"groupId":"OG001","value":"33.5","lowerLimit":"13.3","upperLimit":"84.4"}]}]},{"title":"Serotype 2; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39.9","lowerLimit":"25.2","upperLimit":"63.1"},{"groupId":"OG001","value":"41.6","lowerLimit":"17.0","upperLimit":"102"}]}]},{"title":"Serotype 2; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"306","lowerLimit":"221","upperLimit":"424"},{"groupId":"OG001","value":"39.0","lowerLimit":"16.7","upperLimit":"91.3"}]}]},{"title":"Serotype 2; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"292","lowerLimit":"217","upperLimit":"395"},{"groupId":"OG001","value":"30.0","lowerLimit":"13.8","upperLimit":"64.9"}]}]},{"title":"Serotype 3; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","lowerLimit":"27.3","upperLimit":"55.4"},{"groupId":"OG001","value":"33.2","lowerLimit":"16.1","upperLimit":"68.5"}]}]},{"title":"Serotype 3; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"296","lowerLimit":"230","upperLimit":"381"},{"groupId":"OG001","value":"32.4","lowerLimit":"14.8","upperLimit":"71.0"}]}]},{"title":"Serotype 3; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"287","lowerLimit":"219","upperLimit":"376"},{"groupId":"OG001","value":"29.5","lowerLimit":"14.2","upperLimit":"61.1"}]}]},{"title":"Serotype 4; Pre-Injection 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"12.5","upperLimit":"23.5"},{"groupId":"OG001","value":"21.3","lowerLimit":"11.3","upperLimit":"40.1"}]}]},{"title":"Serotype 4; Post-Injection 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"152","lowerLimit":"115","upperLimit":"201"},{"groupId":"OG001","value":"21.7","lowerLimit":"10.0","upperLimit":"46.9"}]}]},{"title":"Serotype 4; Post-Injection 3","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"155","lowerLimit":"125","upperLimit":"191"},{"groupId":"OG001","value":"16.5","lowerLimit":"9.17","upperLimit":"29.7"}]}]}]},{"type":"PRIMARY","title":"GMT of Flavivirus-Naïve Participants Against Each Serotype With the Parental Dengue Virus Strains Before and After Vaccinations With Either CYD Dengue Vaccine or a Placebo","description":"GMTs of antibodies against the dengue virus serotypes (1, 2, 3, and 4) were assessed using the Dengue PRNT. Flavivirus-Naive participants were defined as participants without quantified antibodies against Japanese encephalitis and without antibody quantified against all serotypes (1, 2, 3, and 4) with parental dengue virus strains in the baseline sample.","populationDescription":"Analysis was performed on Full analysis set. Here, \"overall number of participants analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers (1/dilution)","timeFrame":"Pre-Injection 1 and Post- Injections 2 and 3","groups":[{"id":"OG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months."},{"id":"OG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"19"}]}],"classes":[{"title":"Serotype 1; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 1; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"47.1","lowerLimit":"35.3","upperLimit":"62.9"},{"groupId":"OG001","value":"5.98","lowerLimit":"4.62","upperLimit":"7.74"}]}]},{"title":"Serotype 1; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"81.6","lowerLimit":"66.3","upperLimit":"101"},{"groupId":"OG001","value":"7.38","lowerLimit":"3.88","upperLimit":"14.0"}]}]},{"title":"Serotype 2; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 2; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"71.4","lowerLimit":"55.4","upperLimit":"92.1"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 2; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"97.5","lowerLimit":"77.5","upperLimit":"123"},{"groupId":"OG001","value":"6.03","lowerLimit":"4.43","upperLimit":"8.21"}]}]},{"title":"Serotype 3; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 3; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"116","lowerLimit":"92.6","upperLimit":"146"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 3; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"117","lowerLimit":"97.4","upperLimit":"141"},{"groupId":"OG001","value":"6.17","lowerLimit":"4.52","upperLimit":"8.41"}]}]},{"title":"Serotype 4; Pre-Injection 1","categories":[{"measurements":[{"groupId":"OG000","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"},{"groupId":"OG001","value":"5.00","lowerLimit":"5.00","upperLimit":"5.00"}]}]},{"title":"Serotype 4; Post-Injection 2","categories":[{"measurements":[{"groupId":"OG000","value":"73.3","lowerLimit":"53.7","upperLimit":"100"},{"groupId":"OG001","value":"5.95","lowerLimit":"4.47","upperLimit":"7.91"}]}]},{"title":"Serotype 4; Post-Injection 3","categories":[{"measurements":[{"groupId":"OG000","value":"78.0","lowerLimit":"62.0","upperLimit":"98.1"},{"groupId":"OG001","value":"5.54","lowerLimit":"4.47","upperLimit":"6.87"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Adverse events (AEs) were collected from Day 0 (post-vaccination) up to 6 months post-Injection 3 (up to 18 months)","description":"Analysis was performed on Safety analysis set.","eventGroups":[{"id":"EG000","title":"CYD Dengue Vaccine Group","description":"Participants received 3 injections of the CYD dengue vaccine, 1 injection each at 0, 6, and 12 months.","deathsNumAffected":0,"deathsNumAtRisk":199,"seriousNumAffected":11,"seriousNumAtRisk":199,"otherNumAffected":138,"otherNumAtRisk":199},{"id":"EG001","title":"Placebo Group","description":"Participants received 3 injections of placebo, 1 injection each at 0, 6, and 12 months.","deathsNumAffected":0,"deathsNumAtRisk":51,"seriousNumAffected":7,"seriousNumAtRisk":51,"otherNumAffected":29,"otherNumAtRisk":51}],"seriousEvents":[{"term":"Overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Skull fractured base","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]},{"term":"Fibrous dysplasia of bone","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":51}]},{"term":"Febrile convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"VIIth nerve paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Acute tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Enterocolitis infectious","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Gastroenteritis rotavirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Pharyngotonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]},{"term":"Scarlet fever","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":51}]},{"term":"Viral pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]}],"otherEvents":[{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":24,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]},{"term":"Headache; Post-Any Injection","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":104,"numAffected":104,"numAtRisk":199},{"groupId":"EG001","numEvents":20,"numAffected":20,"numAtRisk":51}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":199},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":51}]},{"term":"Injection site Pain; Post-Any","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":138,"numAffected":138,"numAtRisk":199},{"groupId":"EG001","numEvents":29,"numAffected":29,"numAtRisk":51}]},{"term":"Injection site Erythema; Post-Any","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":93,"numAffected":93,"numAtRisk":199},{"groupId":"EG001","numEvents":25,"numAffected":25,"numAtRisk":51}]},{"term":"Injection site Swelling; Post-Any","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":77,"numAffected":77,"numAtRisk":199},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":51}]},{"term":"Asthenia; Post-Any Injection","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":94,"numAffected":94,"numAtRisk":199},{"groupId":"EG001","numEvents":17,"numAffected":17,"numAtRisk":51}]},{"term":"Fever; Post-Any Injection","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":58,"numAtRisk":198},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":51}]},{"term":"Malaise; Post-Any Injection","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":108,"numAffected":108,"numAtRisk":199},{"groupId":"EG001","numEvents":21,"numAffected":21,"numAtRisk":51}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":199},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":51}]},{"term":"Myalgia; Post-Any Injection","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":75,"numAffected":75,"numAtRisk":199},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":51}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":61,"numAffected":50,"numAtRisk":199},{"groupId":"EG001","numEvents":15,"numAffected":11,"numAtRisk":51}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"None reported"},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications."},"pointOfContact":{"title":"Director","organization":"Sanofi Pasteur SA","email":"Contact-US@sanofi.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003715","term":"Dengue"},{"id":"D019595","term":"Severe Dengue"}],"ancestors":[{"id":"D000096724","term":"Mosquito-Borne Diseases"},{"id":"D000079426","term":"Vector Borne Diseases"},{"id":"D007239","term":"Infections"},{"id":"D001102","term":"Arbovirus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D018177","term":"Flavivirus Infections"},{"id":"D018178","term":"Flaviviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D006482","term":"Hemorrhagic Fevers, Viral"}]},"interventionBrowseModule":{"meshes":[{"id":"D012965","term":"Sodium Chloride"}],"ancestors":[{"id":"D002712","term":"Chlorides"},{"id":"D006851","term":"Hydrochloric Acid"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017670","term":"Sodium Compounds"}]}},"hasResults":true}